Skip to main content

Table 5 Univariate and multivariate analysis for event-free survival

From: The prognostic value of 18F-FDG PET/CT intra-tumoural metabolic heterogeneity in pretreatment neuroblastoma patients

Survival analysis
Variable Univariate Multivariate
HR (95 % CI) P HR (95 % CI) P
Age 1.106 (0.895-1.367) 0.351   
Tumor primary site 0.337(0.045-2.533) 0.291   
MYCN 1.492(0.605-3.680) 0.385   
1p 1.202(0.794-1.820) 0.384   
11q 1.529(1.035-2.259) 0.033*   0.359
INSS stage 3.508(0.922-13.551) 0.066   
COG group 4.719(1.474-15.113) 0.009*   0.125
NSE 1.000(1.000-1.001) 0.256   
LDH 1.000(1.000-1.001) 0.336   
PHOX2B 1.000(1.000-1.001) 0.212   
BMI 6.336(1.426-28.153) 0.015* 4.677(1.032-21.205) 0.045*
SUVmean 0.981(0.644-1.493) 0.928   
SUVmax 1.083(0.949-1.237) 0.237   
SUVpeak 1.085(0.912-1.290) 0.358   
MTVtotal 1.000(0.999-1.002) 0.615   
MTV40% 1.000(0.997-1.003) 0.9   
TLGtotal 1.000(0.999-1.001) 0.918   
TLG40% 1.000(0.999-1.001) 0.804   
AUC-CSHtotal 0.001(0.001-0.164) 0.007* 0.005(0.000-0.705) 0.036*
AUC-CSH40% 0.001(0.001-1.103) 0.052   
  1. MYCN myelocytomatosis viral oncogene neuroblastoma derived homolog, INSS International Neuroblastoma Staging System, COG Children's Oncology Group, NSE neuron-specific enolase, LDH lactate dehydrogenase, PHOX2B paired-like homebox 2B, BMI bone morrow involvement, SUVmean the mean standardized uptake value, SUVmax the maximum standard uptake value, SUVpeak the peak standardized uptake value, MTV metabolic tumour volume, TLG total lesion glycolysis, AUC-CSH areas under the curve of cumulative SUV-volume histogram, HR: hazard rate, CI confidence interval, *P < 0.05